{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:57:22Z","timestamp":1793908642267,"version":"4.8.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","award":["NNF21SA0072746"],"award-info":[{"award-number":["NNF21SA0072746"]}],"id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF19OC0055001"],"award-info":[{"award-number":["NNF19OC0055001"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF23OC0084970"],"award-info":[{"award-number":["NNF23OC0084970"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF24OC0088402"],"award-info":[{"award-number":["NNF24OC0088402"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF25OC0105136"],"award-info":[{"award-number":["NNF25OC0105136"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["1052\\u201300003B"],"award-info":[{"award-number":["1052\\u201300003B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["10.46540\/4308\\u201300056B"],"award-info":[{"award-number":["10.46540\/4308\\u201300056B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["10.46540\/4285\\u201300131B"],"award-info":[{"award-number":["10.46540\/4285\\u201300131B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.peptides.2025.171462","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T23:18:41Z","timestamp":1766272721000},"page":"171462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Distinct and complementary metabolic effects of GLP-1 and glucagon receptor agonism in diet-induced obese mice"],"prefix":"10.1016","volume":"195","author":[{"given":"Marie","family":"Winther-S\u00f8rensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.J.","family":"Trammell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens","family":"Vyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Serizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha J.","family":"Grevengoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune E.","family":"Kuhre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai J.","family":"Wewer Albrechtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2025.171462_bib1","doi-asserted-by":"crossref","unstructured":"Z.M. Younossi, M. Kalligeros, L. Henry, Epidemiology of metabolic dysfunction-associated steatotic liver disease, Clin Mol Hepatol 31(Suppl) (2025) S32-s50.","DOI":"10.3350\/cmh.2024.0431"},{"issue":"11","key":"10.1016\/j.peptides.2025.171462_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.peptides.2025.171462_bib3","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-13-0414","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS","volume":"221","author":"van Bloemendaal","year":"2014","journal-title":"J. Endocrinol."},{"issue":"6","key":"10.1016\/j.peptides.2025.171462_bib4","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.peptides.2025.171462_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/dom.12585","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.peptides.2025.171462_bib6","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/db12-0797","article-title":"Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia","volume":"62","author":"Tan","year":"2013","journal-title":"Diabetes"},{"issue":"7798","key":"10.1016\/j.peptides.2025.171462_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis","volume":"579","author":"Perry","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.peptides.2025.171462_bib8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cmet.2008.09.008","article-title":"The glucagon receptor is required for the adaptive metabolic response to fasting","volume":"8","author":"Longuet","year":"2008","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.peptides.2025.171462_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.peptides.2025.171462_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101850","article-title":"Evaluation of long acting GLP1R\/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1\/glucagon agonism in NASH patients","volume":"79","author":"Monfeuga","year":"2024","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2025.171462_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.735019","article-title":"Striking the Balance: GLP-1\/Glucagon Co-Agonism as a Treatment Strategy for Obesity","volume":"12","author":"Hope","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.peptides.2025.171462_bib12","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-023-05929-0","article-title":"Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy","author":"Tsch\u00f6p","year":"2023","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.peptides.2025.171462_bib13","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-Like Peptide 1\/Glucagon Receptor Dual Agonism Reverses Obesity in Mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.peptides.2025.171462_bib14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.peptides.2025.171462_bib15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171462_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"8","key":"10.1016\/j.peptides.2025.171462_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114501","article-title":"Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans","volume":"43","author":"Jacobsen","year":"2024","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.peptides.2025.171462_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105296","article-title":"Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells","volume":"25","author":"Elmelund","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.peptides.2025.171462_bib19","doi-asserted-by":"crossref","DOI":"10.2337\/db23-0858","article-title":"Glucagon resistance in individuals with obesity and hepatic steatosis can be measured using the GLUSENTIC test and index","author":"Kjeldsen","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2025.171462_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmet.2018.07.001","article-title":"Exercise-induced molecular mechanisms promoting glycogen supercompensation in human skeletal muscle","volume":"16","author":"Hingst","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2025.171462_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/0003-2697(68)90127-9","article-title":"A rapid filter paper assay for UDPglucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose","volume":"25","author":"Thomas","year":"1968","journal-title":"Anal. Biochem."},{"issue":"1","key":"10.1016\/j.peptides.2025.171462_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0165-022X(80)90004-4","article-title":"A rapid colorimetric assay for carbamyl phosphate synthetase I","volume":"3","author":"Pierson","year":"1980","journal-title":"J. Biochem Biophys. Methods"},{"issue":"1","key":"10.1016\/j.peptides.2025.171462_bib23","first-page":"E23","article-title":"Regulation of hepatic free fatty acid metabolism by glucagon and insulin","volume":"237","author":"Witters","year":"1979","journal-title":"Am. J. Physiol."},{"issue":"1","key":"10.1016\/j.peptides.2025.171462_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/bj2640093","volume":"264","author":"P\u00e9gorier","year":"1989","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.peptides.2025.171462_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00125-017-4535-5","article-title":"Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids","volume":"61","author":"Wewer Albrechtsen","year":"2018","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.peptides.2025.171462_bib26","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/dom.14173","article-title":"Amino acids are sensitive glucagon receptor-specific biomarkers for glucagon-like peptide-1 receptor\/glucagon receptor dual agonists","volume":"22","author":"Li","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.peptides.2025.171462_bib27","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1177\/193229681000400607","article-title":"The physiology of glucagon","volume":"4","author":"Taborsky","year":"2010","journal-title":"J. Diabetes Sci. Technol."},{"issue":"9","key":"10.1016\/j.peptides.2025.171462_bib28","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2337\/db17-1502","article-title":"Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.peptides.2025.171462_bib29","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.2337\/db14-0242","article-title":"Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake","volume":"63","author":"Cegla","year":"2014","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.peptides.2025.171462_bib30","doi-asserted-by":"crossref","first-page":"R1674","DOI":"10.1152\/ajpregu.1998.275.5.R1674","article-title":"Apparent thermogenic effect of injected glucagon is not due to a direct effect on brown fat cells","volume":"275","author":"Dicker","year":"1998","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.peptides.2025.171462_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molmet.2019.01.011","article-title":"The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice","volume":"22","author":"Beaudry","year":"2019","journal-title":"Mol. Metab."},{"issue":"11","key":"10.1016\/j.peptides.2025.171462_bib32","article-title":"Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss","volume":"3","author":"Hope","year":"2022","journal-title":"Cell Rep. Med"},{"issue":"5","key":"10.1016\/j.peptides.2025.171462_bib33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","article-title":"Fibroblast growth factor 21 mediates specific glucagon actions","volume":"62","author":"Habegger","year":"2013","journal-title":"Diabetes"},{"issue":"21","key":"10.1016\/j.peptides.2025.171462_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215407","article-title":"Glucagon Regulation of Energy Expenditure","volume":"20","author":"Kleinert","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.peptides.2025.171462_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101639","article-title":"Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice","volume":"66","author":"Galsgaard","year":"2022","journal-title":"Mol. Metab."},{"issue":"11","key":"10.1016\/j.peptides.2025.171462_bib36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1463-1326.2011.01427.x","article-title":"Glucagon antagonism as a potential therapeutic target in type 2 diabetes","volume":"13","author":"Bagger","year":"2011","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.peptides.2025.171462_bib37","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a Glucagon Receptor Antagonist, Increases Liver Fat in Patients with Type 2 Diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.peptides.2025.171462_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.peptides.2025.171462_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.peptides.2025.171462_bib40","first-page":"db200440","article-title":"Glucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia","author":"Kramer","year":"2020","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.peptides.2025.171462_bib41","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/s42255-023-00938-0","article-title":"Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes","volume":"5","author":"Parker","year":"2023","journal-title":"Nat. Metab."},{"issue":"10","key":"10.1016\/j.peptides.2025.171462_bib42","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrendo.2017.80","article-title":"Regulation of hepatic glucose metabolism in health and disease","volume":"13","author":"Petersen","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.peptides.2025.171462_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101801","article-title":"Results from three phase 1 trials of NNC9204-1177, a glucagon\/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity","volume":"78","author":"Friedrichsen","year":"2023","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.peptides.2025.171462_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.2007.03001.x","article-title":"Muscular exercise can cause highly pathological liver function tests in healthy men","volume":"65","author":"Pettersson","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7871","key":"10.1016\/j.peptides.2025.171462_bib45","first-page":"1","article-title":"A glucagonoma syndrome","volume":"2","author":"Mallinson","year":"1974","journal-title":"Lancet (Lond. Engl. )"},{"issue":"8","key":"10.1016\/j.peptides.2025.171462_bib46","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/gut.31.8.946","article-title":"Increased amino acid clearance and urea synthesis in a patient with glucagonoma","volume":"31","author":"Almdal","year":"1990","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.peptides.2025.171462_bib47","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.tem.2016.06.010","article-title":"Amino Acid Sensing in Skeletal Muscle","volume":"27","author":"Moro","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2025.171462_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol. Metab."},{"issue":"7","key":"10.1016\/j.peptides.2025.171462_bib49","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.peptides.2025.171462_bib50","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/s42255-023-00938-0","article-title":"Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes","volume":"5","author":"Parker","year":"2023","journal-title":"Nat. Metab."},{"issue":"6","key":"10.1016\/j.peptides.2025.171462_bib51","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978125001238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978125001238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:22:46Z","timestamp":1773948166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978125001238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"alternative-id":["S0196978125001238"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2025.171462","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct and complementary metabolic effects of GLP-1 and glucagon receptor agonism in diet-induced obese mice","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2025.171462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"171462"}}